Cytena, a medtech spin-out of Freiburg University, has raised €1.1m ($1.25m) to support the development of its cell separation device.
High-Tech Gründerfonds (HTGF) led a consortium of private investors in the seed round, which will be used to launch Cytena’s device, cy-clone, and duel its marketing activities.
André Gross, technical director of Cytena, said: “Currently, we are in particularly close contact with cell line development units in the pharmaceutical industry e. g. for biologicals and with researchers in the field…
